title: Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines.
abstract: Nowadays, treatment of food allergy only considered the avoidance of the specific food. However, the possibility of cross-reactivity makes this practice not very effective. Immunotherapy may exhibit as a good alternative to food allergy treatment. The use of hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool which could be developed for immunotherapy. In this study, three mutants of Pru p 3, the principal allergen of peach, were produced based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named as Pru p 3.01, Pru p 3.02, and Pru p 3.03. Pru p 3.01 showed very similar allergenic activity as the wild type by in vitro assays. However, Pru p 3.02 and Pru p 3.03 presented reduced IgE binding with respect to the native form, by in vitro, ex vivo, and in vivo assays. In addition, Pru p 3.03 had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by specific antibodies anti-Pru p 3. Nevertheless, both Pru p 3.02 and Pru p 3.03 maintained the binding to IgG1 and their ability to activate T lymphocytes. Thus, Pru p 3.02 and Pru p 3.03 could be good candidates for potential immunotherapy in peach-allergic patients.
authors: Centro de Biotecnología y Genómica de Plantas (UPM-INIA), Campus de Montegancedo, Pozuelo de Alarcón, 28223 Madrid, Spain.
authors: C
authors: C
authors: Gómez-Casado
authors: M
authors: M
authors: Garrido-Arandia
authors: P
authors: P
authors: Gamboa
authors: N
authors: N
authors: Blanca-López
authors: G
authors: G
authors: Canto
authors: J
authors: J
authors: Varela
authors: J
authors: J
authors: Cuesta-Herranz
authors: L F
authors: LF
authors: Pacios
authors: A
authors: A
authors: Díaz-Perales
authors: L
authors: L
authors: Tordesillas
mesh_terms: D000293:Adolescent; D000328:Adult; D000595:Amino Acid Sequence; D019138:Antibodies, Blocking / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D052179:Antigens, Plant / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D005260:Female; D005512:Food Hypersensitivity / Q000276:immunology / Q000628:therapy; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D050505:Mutant Proteins / Q000276:immunology*; D010940:Plant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D011485:Protein Binding / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000276:immunology*; D055815:Young Adult
chemical_list: D019138:Antibodies, Blocking; D052179:Antigens, Plant; D007074:Immunoglobulin G; D050505:Mutant Proteins; D010940:Plant Proteins; C463181:Pru p 3 allergen; D014612:Vaccines; D007073:Immunoglobulin E